

PROMOTION RECOMMENDATION
THE UNIVERSITY OF MICHIGAN
MEDICAL SCHOOL
DEPARTMENT OF UROLOGY

Todd M. Morgan, M.D., associate professor of urology, with tenure, Department of Urology, Medical School, is recommended for promotion to professor of urology, with tenure, Department of Urology, Medical School.

Academic Degrees:

M.D.	2003	Harvard Medical School, Boston, MA
B.A.	1999	Harvard University, Cambridge, MA

Professional Record:

2016-present	Associate Professor of Urology, University of Michigan
2012-2016	Assistant Professor of Urology, University of Michigan
2011-2012	Assistant Professor of Urologic Surgery, Vanderbilt University
2009-2011	Clinical Instructor of Urologic Surgery, Vanderbilt University

Summary of Evaluation:

Teaching: Dr. Morgan has dedicated approximately 10% of his effort to teaching and educational activities in the clinic, inpatient wards, and operating room within the field of urologic oncology. He mentors undergraduate students in the laboratory as well as provides shadowing experiences in the clinic for pre-med third year and fourth year students. Dr. Morgan serves as a research mentor to a large number of medical students interested in urology. A critical component of his teaching is the supervision and training of urology residents in the Cancer Center outpatient clinic, centered on the evaluation of complex urologic cancers, and in the operating room, focused on performing open, laparoscopic, and robotic surgeries. Dr. Morgan has given educational talks around the state to health care providers as well as patient support groups. Notably, he played a major role in the development of the national testis cancer curriculum for Urologic Oncology Fellows. In 2018, Dr. Morgan developed and directed a well-received course on genetic testing in prostate cancer at the annual meeting of the American Urological Association. He directed the Department of Urology's monthly morbidity and mortality teaching conference for five years through 2017.

Research: Dr. Morgan's research spans the spectrum from bench-based translational science to clinical research. His research laboratory focuses on biomarkers associated with cancer treatment efficacy, aiming to facilitate precision-based therapies, and to help understand key mechanisms of disease resistance. Dr. Morgan has developed a liquid biopsy program for prostate cancer at the University of Michigan that serves as an important resource for investigators. Another research focus is the genomic characterization of localized prostate cancer and the clinical evaluation of tissue-based molecular signatures within a randomized clinical trial. His laboratory is also invested in identifying novel molecular diagnostics, such as prognostic and predictive biomarkers, in other urologic cancers. Dr. Morgan has published more than 150 peer-reviewed articles, and written two books. He is the principal investigator for seven grants totaling \$4.5M, including an R01 from the National Cancer Institute, and is a co-investigator on a P01 Prostate Cancer Foundation Challenge award also from the National Cancer Institute. In 2018, Dr. Morgan received the Society of Urologic Oncology Young Investigator Award, an honor bestowed on the most accomplished

urologic oncologist within ten years of graduation from residency. Dr. Morgan serves as an associate editor for *European Urology* and is a reviewer for 17 additional scientific journals.

Recent and Significant Publications:

Salami SS, Singhal U, Spratt DE, Palapattu GS, Hollenbeck BK, Schonhoft JD, Graf R, Louw J, Jendrisak A, Dugan L, Wang Y, Tomlins SA, Dittamore R, Feng FY, Morgan TM: Circulating tumor cells as a predictor of treatment response in clinically localized prostate cancer. *JCO Precision Oncology* 2019 published online: <https://ascopubs.org/doi/abs/10.1200/PO.18.00352>.

Hu J, Tosoian JJ, Qi J, Kaye D, Johnson A, Linsell S, Montie JE, Ghani KR, Miller DC, Wojno K, Burks FN, Spratt DE, Morgan TM: Clinical utility of gene expression classifiers in men with newly diagnosed prostate cancer. *JCO Precision Oncology* 2018 published online: <https://ascopubs.org/doi/10.1200/PO.18.00163>.

Morgan TM, Mehra R, Tiemeny P, Wolf JS, Wu S, Sangale S, Brawer M, Stone S, Wu CL, Feldman AS: A multigene signature based on cell cycle proliferation improves prediction of mortality within 5 yr of radical nephrectomy for renal cell carcinoma. *European Urology* 73(5):763-769, 2017. PMID: 29249291

Singhal U, Wang Y, Henderson J, Niknafs YS, Qiao Y, Gursky A, Zaslavsky A, Chung JS, Smith DC, Karnes RJ, Chang SL, Feng FY, Palapattu GS, Taichman RS, Chinnaiyan AM, Tomlins SA, Morgan TM: Multigene profiling of CTCs in mCRPC identifies a clinically relevant prognostic signature. *Molecular Cancer Research* 16(4):643-654, 2018. PMID: 29453313

Hovelson DH, Liu CJ, Yugang W, Kang Q, Henderson J, Gursky A, Brockman S, Ramnath N, Krauss JC, Talpaz M, Kandarpa M, Chugh R, Tuck M, Herman K, Grasso CS, Quist MJ, Feng FY, Haakenson C, Langmore J, Kamberov E, Tesmer T, Husain H, Lonigro RJ, Robinson D, Smith DC, Alva AS, Hussain MH, Chinnaiyan AM, Tewari M, Mills RE, Morgan TM, Tomlins SA: Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. *Oncotarget* 8(52):89848-89866, 2017.

Service: Dr. Morgan is a member of six professional societies, including the American Urological Association, American Society of Clinical Oncology, and Southwest Oncology Group. He currently serves as a panel member for the National Comprehensive Cancer Network Prostate Cancer Early Detection Guidelines. In 2016, he served as the president of the board of the Young Urologic Oncologists of the Society of Urology Oncology. He has served as a member of the Society of Urologic Oncology Finance Committee and the Genitourinary American Society of Clinical Oncology Program Planning Committee. In the Department of Urology, Dr. Morgan is a member of the Cancer Work Group and the Resident Clinical Competency Committee, and he is the division chief of Urologic Oncology, that is among the largest in the country.

External Reviewers:

Reviewer A: "Prior to reviewing the promotion information provided, I was well aware of Dr. Morgan's work on genomic markers in urologic cancer as well as his work in clinical research ranging from outcomes studies and telemedicine in urology...Dr. Morgan's work on a multi-gene signature based on cell cycle proliferation in renal cell carcinoma is the first work defining a predictor of mortality and recurrence for patients with seemingly localized kidney cancer."

Reviewer B: “While [his] prolific publication output is commendable, and easily exceeds the requirements for Professorship at [my institution], more importantly, a number of these papers have significantly advanced our understanding of disease biology and have direct translational relevance to enhance patient care...he has achieved a stellar regional, national, and international reputation for his work. He is regarded among the very top of his peer-group in the field of urologic oncology.”


Reviewer C: “He has published more than 150 peer-reviewed papers...This places him in the highest 10 percent in our field (and is higher if adjusted for his age). Many of these reports reflect original work funded by peer-reviewed sources (to date he has contributed to more than \$5 million in research income)...his most successful first author publication is ‘*Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma*’ which has been cited 89 times since publication in 2011 and is within the top 10%...”

Reviewer D: “I am aware of Dr. Morgan’s contributions to our field for almost 10 years even dating back to his contributions in publications while he was a resident at the University of Washington School of Medicine. During this he has distinguished himself as [a] talented and increasingly renowned surgeon and academician with a national reputation...Compared to his peer group I would consider Dr. Morgan a star in the field well above those as a similar stage of career in academic medicine.”

Reviewer E: “Of particular importance is his work in the area of biomarker discovery and biomarker utilization in prostate (and more recently kidney) cancer...His publication on the characterization and sequencing of CTCs [circulating tumor cells] from men with high risk prostate cancer is particularly compelling to me personally, and demonstrates the potential power of such technologies to characterize disease at earlier stages than the conventional work in the setting of metastasis...Dr. Morgan has a significant amount of support from the NIH, including a new RO1 which is a true rarity in the field of urology, as well as foundations such as PCF and commercial entities in the biomarker space.”

Summary of Recommendation:

Dr. Morgan is a urologic oncologist with a clinical focus on evaluating and treating patients with prostate, kidney and bladder cancer. He has developed a high level of expertise in the performance of complex surgery. His research is well-funded and his work is very impactful. I am pleased, therefore, to recommend Todd M. Morgan, M.D. for promotion to professor of urology, with tenure, Department of Urology, Medical School.



Marschall S. Runge, M.D., Ph.D.
Executive Vice President for Medical Affairs
Dean, Medical School